Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study.
cancer biomarkers
cancer-specific mutations
circulating tumor DNA
genomics
liquid biopsies
malignant pleural mesothelioma
plasma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
08
04
2021
revised:
10
05
2021
accepted:
11
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is a fatal tumor with a poor prognosis. The recent developments of liquid biopsies could provide novel diagnostic and prognostic tools in oncology. However, there is limited information about the feasibility of this technique for MPMs. Here, we investigate whether cancer-specific DNA sequences can be detected in pleural fluids and plasma of MPM patients as free circulating tumor DNA (ctDNA). We performed whole-exome sequencing on 14 tumor biopsies from 14 patients, and we analyzed 20 patient-specific somatic mutations with digital droplet PCR (ddPCR) in pleural fluids and plasma, using them as cancer-specific tumor biomarkers. Most of the selected mutations could be detected in pleural fluids (94%) and, noteworthy, in plasma (83%) with the use of ddPCR. Pleural fluids showed similar levels of somatically mutated ctDNA (median = 12.75%, average = 16.3%, standard deviation = 12.3) as those detected in solid biopsies (median = 21.95%; average = 22.21%; standard deviation = 9.57), and their paired difference was weakly statistically significant ( We found robust evidence that mutated DNA is spilled from MPMs, mostly into pleural fluids, proving the concept that liquid biopsies are feasible for MPM patients.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant pleural mesothelioma (MPM) is a fatal tumor with a poor prognosis. The recent developments of liquid biopsies could provide novel diagnostic and prognostic tools in oncology. However, there is limited information about the feasibility of this technique for MPMs. Here, we investigate whether cancer-specific DNA sequences can be detected in pleural fluids and plasma of MPM patients as free circulating tumor DNA (ctDNA).
METHODS
METHODS
We performed whole-exome sequencing on 14 tumor biopsies from 14 patients, and we analyzed 20 patient-specific somatic mutations with digital droplet PCR (ddPCR) in pleural fluids and plasma, using them as cancer-specific tumor biomarkers.
RESULTS
RESULTS
Most of the selected mutations could be detected in pleural fluids (94%) and, noteworthy, in plasma (83%) with the use of ddPCR. Pleural fluids showed similar levels of somatically mutated ctDNA (median = 12.75%, average = 16.3%, standard deviation = 12.3) as those detected in solid biopsies (median = 21.95%; average = 22.21%; standard deviation = 9.57), and their paired difference was weakly statistically significant (
CONCLUSIONS
CONCLUSIONS
We found robust evidence that mutated DNA is spilled from MPMs, mostly into pleural fluids, proving the concept that liquid biopsies are feasible for MPM patients.
Identifiants
pubmed: 34070018
pii: cancers13102445
doi: 10.3390/cancers13102445
pmc: PMC8157824
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Pisa
ID : 153/16
Références
Acta Biomed. 2017 Aug 23;88(2):134-142
pubmed: 28845826
BMC Cancer. 2012 Sep 25;12:428
pubmed: 23009708
Clin Cancer Res. 2012 Feb 1;18(3):598-604
pubmed: 22065079
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
Mol Cancer. 2019 Jul 3;18(1):114
pubmed: 31269959
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
J Thorac Oncol. 2012 Mar;7(3):587-94
pubmed: 22307011
Clin Cancer Res. 2018 Mar 15;24(6):1500-1510
pubmed: 29284708
Breast Cancer Res Treat. 2019 Nov;178(1):57-62
pubmed: 31346846
Adv Exp Med Biol. 2016;882:235-58
pubmed: 26987538
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Int J Mol Sci. 2019 Aug 14;20(16):
pubmed: 31416192
Front Oncol. 2020 Sep 09;10:1742
pubmed: 33014860
Cancers (Basel). 2019 Jul 05;11(7):
pubmed: 31284524
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25543-25552
pubmed: 32999071
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Lung Cancer. 2018 Oct;124:19-22
pubmed: 30268460
Expert Rev Anticancer Ther. 2019 Oct;19(10):869-878
pubmed: 31533487
Eur J Cancer. 2007 Dec;43(18):2722-8
pubmed: 17980576
Oncogene. 2018 May;37(20):2645-2659
pubmed: 29507420
Ann Transl Med. 2015 Aug;3(13):182
pubmed: 26366399